| Stage 4S neuroblastoma: what makes it special? |
| KK Matthay |
|
JCO Jun 1 1998: 2003–2006.
[PDF]
|
 |
|
Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study |
| |
HM Katzenstein, LC Bowman, GM Brodeur, PS Thorner, VV Joshi, EI Smith, AT Look, ST Rowe, MB Nash, T Holbrook, C Alvarado, PV Rao, RP Castleberry, and SL Cohn |
| |
JCO Jun 1 1998: 2007–2017.
[Abstract]
[PDF]
|
|
|
Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes |
| |
J Ragaz and A Coldman |
| |
JCO Jun 1 1998: 2018–2024.
[Abstract]
[PDF]
|
|
|
bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: correlation with 10-year follow-up |
| |
C Charpin, S Garcia, P Bonnier, F Martini, L Andrac, N Horschowski, MN Lavaut, and C Allasia |
| |
JCO Jun 1 1998: 2025–2031.
[Abstract]
[PDF]
|
|
|
Phase II trial of paclitaxel and topotecan with granulocyte colony- stimulating factor support in stage IV breast cancer |
| |
GF Fleming, JW Kugler, PC Hoffman, R Ansari, JD Bitran, A Klepsch, D Malone, AA Fasanmade, MJ Ratain, and EE Vokes |
| |
JCO Jun 1 1998: 2032–2037.
[Abstract]
[PDF]
|
|
|
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group |
| |
GN Hortobagyi, RL Theriault, A Lipton, L Porter, D Blayney, C Sinoff, H Wheeler, JF Simeone, JJ Seaman, RD Knight, M Heffernan, K Mellars, and DJ Reitsma |
| |
JCO Jun 1 1998: 2038–2044.
[Abstract]
[PDF]
|
|
|
Family history and treatment outcome in young women after breast- conserving surgery and radiation therapy for early-stage breast cancer |
| |
E Chabner, A Nixon, R Gelman, S Hetelekidis, A Recht, B Bornstein, J Connolly, S Schnitt, B Silver, J Manola, J Harris, and J Garber |
| |
JCO Jun 1 1998: 2045–2051.
[Abstract]
[PDF]
|
|
|
Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? |
| |
V Leblond, F Davi, F Charlotte, R Dorent, MO Bitker, L Sutton, I Gandjbakhch, JL Binet, and M Raphael |
| |
JCO Jun 1 1998: 2052–2059.
[Abstract]
[PDF]
|
|
|
Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie |
| |
V Leblond, T Ben-Othman, E Deconinck, AL Taksin, JL Harousseau, MA Delgado, A Delmer, F Maloisel, X Mariette, P Morel, JP Clauvel, P Duboisset, S Entezam, O Hermine, M Merlet, I Yakoub-Agha, O Guibon, H Caspard, and N Fort |
| |
JCO Jun 1 1998: 2060–2064.
[Abstract]
[PDF]
|
|
|
Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis |
| |
H Gomez, M Hidalgo, L Casanova, R Colomer, DL Pen, J Otero, W Rodriguez, C Carracedo, H Cortes-Funes, and C Vallejos |
| |
JCO Jun 1 1998: 2065–2069.
[Abstract]
[PDF]
|
|
|
Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas |
| |
TB Haddy, MA Adde, J McCalla, MJ Domanski, M Datiles, 3rd, SC Meehan, A Pikus, AT Shad, I Valdez, L Lopez Vivino, and IT Magrath |
| |
JCO Jun 1 1998: 2070–2079.
[Abstract]
[PDF]
|
|
|
bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related |
| |
FA Geelen, MH Vermeer, CJ Meijer, SC Van der Putte, E Kerkhof, PM Kluin, and R Willemze |
| |
JCO Jun 1 1998: 2080–2085.
[Abstract]
[PDF]
|
|
|
Role of daunorubicin in the induction therapy for adult acute myeloid leukemia |
| |
N Usui, N Dobashi, T Kobayashi, S Yano, N Maki, O Asai, T Saito, Y Yamaguchi, H Watanabe, A Kato, A Ogihara, M Katori, M Nagamine, Y Takei, H Yamazaki, S Funakoshi, N Tajima, M Ogawa, and Y Kuraishi |
| |
JCO Jun 1 1998: 2086–2092.
[Abstract]
[PDF]
|
|
|
CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients |
| |
AL Pecora, RA Preti, GW Gleim, A Jennis, K Zahos, S Cantwell, L Doria, R Isaacs, AP Gillio, MA Michelis, and JA Brochstein |
| |
JCO Jun 1 1998: 2093–2104.
[Abstract]
[PDF]
|
|
|
Unknown primary tumors metastatic to liver |
| |
JP Ayoub, KR Hess, MC Abbruzzese, R Lenzi, MN Raber, and JL Abbruzzese |
| |
JCO Jun 1 1998: 2105–2112.
[Abstract]
[PDF]
|
|
|
Analytical decision model for the cost-effective management of solitary pulmonary nodules |
| |
SS Gambhir, JE Shepherd, BD Shah, E Hart, CK Hoh, PE Valk, T Emi, and ME Phelps |
| |
JCO Jun 1 1998: 2113–2125.
[Abstract]
[PDF]
|
|
|
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group |
| |
K Furuse, M Fukuoka, Y Nishiwaki, Y Kurita, K Watanabe, K Noda, Y Ariyoshi, T Tamura, and N Saijo |
| |
JCO Jun 1 1998: 2126–2132.
[Abstract]
[PDF]
|
|
|
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group |
| |
G Giaccone, TA Splinter, C Debruyne, GS Kho, P Lianes, N van Zandwijk, MC Pennucci, G Scagliotti, J van Meerbeeck, Q van Hoesel, D Curran, T Sahmoud, and PE Postmus |
| |
JCO Jun 1 1998: 2133–2141.
[Abstract]
[PDF]
|
|
|
Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients |
| |
JF Vansteenkiste, SG Stroobants, PR De Leyn, PJ Dupont, J Bogaert, A Maes, GJ Deneffe, KL Nackaerts, JA Verschakelen, TE Lerut, LA Mortelmans, and MG Demedts |
| |
JCO Jun 1 1998: 2142–2149.
[Abstract]
[PDF]
|
|
|
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer |
| |
S Wojtowicz-Praga, J Torri, M Johnson, V Steen, J Marshall, E Ness, R Dickson, M Sale, HS Rasmussen, TA Chiodo, and MJ Hawkins |
| |
JCO Jun 1 1998: 2150–2156.
[Abstract]
[PDF]
|
|
|
Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies |
| |
GA Masters, DJ Haraf, PC Hoffman, LC Drinkard, SA Krauss, MK Ferguson, J Olak, BL Samuels, HM Golomb, and EE Vokes |
| |
JCO Jun 1 1998: 2157–2163.
[Abstract]
[PDF]
|
|
|
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer |
| |
JD Hainsworth, HA Burris, 3rd, JB Erland, M Thomas, and FA Greco |
| |
JCO Jun 1 1998: 2164–2168.
[Abstract]
[PDF]
|
|
|
Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma |
| |
AL Yu, MM Uttenreuther-Fischer, CS Huang, CC Tsui, SD Gillies, RA Reisfeld, and FH Kung |
| |
JCO Jun 1 1998: 2169–2180.
[Abstract]
[PDF]
|
|
|
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer |
| |
K Clarke, RL Basser, D Maher, DJ Morgan, J Cebon, RM Fox, JS Hill, C Alt, J Bartlett, H Geldard, AH Kaye, and MD Green |
| |
JCO Jun 1 1998: 2181–2187.
[Abstract]
[PDF]
|
|
|
Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report |
| |
SM Chang, JG Kuhn, J Rizzo, HI Robins, SC Schold, Jr, AM Spence, MS Berger, MP Mehta, ME Bozik, I Pollack, M Gilbert, D Fulton, C Rankin, M Malec, and MD Prados |
| |
JCO Jun 1 1998: 2188–2194.
[Abstract]
[PDF]
|
|
|
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma |
| |
BV Taylor, JC Buckner, TL Cascino, JR O'Fallon, PL Schaefer, RP Dinapoli, and P Schomberg |
| |
JCO Jun 1 1998: 2195–2201.
[Abstract]
[PDF]
|
|
|
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results |
| |
DD Bigner, MT Brown, AH Friedman, RE Coleman, G Akabani, HS Friedman, WL Thorstad, RE McLendon, SH Bigner, XG Zhao, CN Pegram, CJ Wikstrand, JE Herndon, 2nd, NA Vick, N Paleologos, I Cokgor, JM Provenzale, and MR Zalutsky |
| |
JCO Jun 1 1998: 2202–2212.
[Abstract]
[PDF]
|
|
|
Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx |
| |
PC Levendag, PI Schmitz, PP Jansen, WM Eijkenboom, AG Visser, IK Kolkman- Deurloo, D Sipkema, LL Visch, and S Senan |
| |
JCO Jun 1 1998: 2213–2220.
[Abstract]
[PDF]
|
|
|
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma |
| |
GL Clayman, AK el-Naggar, SM Lippman, YC Henderson, M Frederick, JA Merritt, LA Zumstein, TM Timmons, TJ Liu, L Ginsberg, JA Roth, WK Hong, P Bruso, and H Goepfert |
| |
JCO Jun 1 1998: 2221–2232.
[Abstract]
[PDF]
|
|
|
Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study |
| |
P Hoskins, E Eisenhauer, S Beare, M Roy, P Drouin, G Stuart, P Bryson, R Grimshaw, V Capstick, and B Zee |
| |
JCO Jun 1 1998: 2233–2237.
[Abstract]
[PDF]
|
|
|
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear |
| |
GB Wisman, H Hollema, S de Jong, J ter Schegget, SP Tjong-A-Hung, MH Ruiters, M Krans, EG de Vries, and AG van der Zee |
| |
JCO Jun 1 1998: 2238–2245.
[Abstract]
[PDF]
|
|
|
Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model |
| |
CJ McGinn, RK Ten Haken, WD Ensminger, S Walker, S Wang, and TS Lawrence |
| |
JCO Jun 1 1998: 2246–2252.
[Abstract]
[PDF]
|
|
|
Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma |
| |
JE Gershenwald, MI Colome, JE Lee, PF Mansfield, C Tseng, JJ Lee, CM Balch, and MI Ross |
| |
JCO Jun 1 1998: 2253–2260.
[Abstract]
[PDF]
|
|
|
Resection of metastatic renal cell carcinoma |
| |
JP Kavolius, DP Mastorakos, C Pavlovich, P Russo, ME Burt, and MS Brady |
| |
JCO Jun 1 1998: 2261–2266.
[Abstract]
[PDF]
|
|
|
Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis |
| |
BD Leibman, O Dillioglugil, PT Scardino, F Abbas, E Rogers, RD Wolfinger, and MW Kattan |
| |
JCO Jun 1 1998: 2267–2271.
[Abstract]
[PDF]
|
|
|
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points |
| |
DJ Bloomfield, MD Krahn, T Neogi, T Panzarella, TJ Smith, P Warde, AR Willan, S Ernst, MJ Moore, A Neville, and IF Tannock |
| |
JCO Jun 1 1998: 2272–2279.
[Abstract]
[PDF]
|
|
| Breast cancer metastatic to the choroid |
| HA Hahm, NE Davidson, JK Giguere, C DiBernardo, and S O'Reilly |
|
JCO Jun 1 1998: 2280–2282.
[PDF]
|
|
| Sharing information with patients |
| M Weber |
|
JCO Jun 1 1998: 2283a.
[PDF]
|
|
| Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? |
| JM Andrieu and P Colonna |
|
JCO Jun 1 1998: 2283b.
[PDF]
|
|
| Oral versus intravenous methotrexate: another opinion |
| BA Kamen, N Winick, and JS Holcenberg |
|
JCO Jun 1 1998: 2283c–2285.
[PDF]
|
|
| Radiation-induced breast cancer after treatment for Hodgkin's disease |
| B Cutuli |
|
JCO Jun 1 1998: 2285–2287.
[PDF]
|
|
| Late solid tumors after treatment for Hodgkin's disease |
| DL Cooper and E Salloum |
|
JCO Jun 1 1998: 2287–2288.
[PDF]
|
|
| Radiotherapy error analysis older than yesterday |
| C Weltens and W Van den Bogaert |
|
JCO Jun 1 1998: 2288–2289.
[PDF]
|
|
| Paclitaxel for the treatment of lymphoma |
| A Younes |
|
JCO Jun 1 1998: 2289–2290.
[PDF]
|
|
| Monitoring methotrexate levels in osteosarcoma |
| R Gorlick, P Meyers, M Kellick, and JR Bertino |
|
JCO Jun 1 1998: 2290–2291.
[PDF]
|
|
| Refractory definitions of tumor response |
| SM Grunberg |
|
JCO Jun 1 1998: 2291–2292.
[PDF]
|
|
| Suicide among cancer patients |
| P Periman |
|
JCO Jun 1 1998: 2292.
[PDF]
|
|
